Pregnancy Outcomes in Women with Type 1 Diabetes Depending on the Different Modes of Insulin Therapy by Gazizova G. et al.
BioNanoScience 2017 vol.7 N2, pages 390-395
Pregnancy Outcomes in Women with Type 1 Diabetes
Depending on the Different Modes of Insulin Therapy
Gazizova G., Gaysina L., Valeeva F., Abakumova A., Sharipova J.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2016, Springer Science+Business Media New York.The aim of the study was to evaluate the
features of the effect of different modes of insulin therapy on pregnancy outcomes in women
with type 1 diabetes mellitus (T1DM) with different levels of albuminuria. The study involved
155 women with T1DM during pregnancy, using various modes of insulin, and 42 infants born to
women  with  T1DM.  In  order  to  identify  a  possible  relationship  between  the  level  of
proinflammatory cytokines and growth factors in pregnant women with T1DM and terms of
delivery, we measured the daily urinary excretion of IL-1β, MCP-1, and TGF-β1 in 21 women at
different trimesters of pregnancy. The use of continuous subcutaneous insulin infusion (CSII) in
pregnant women with T1DM allows to prolong the pregnancy for 2–4 weeks as compared to the
timing of delivery of pregnant women with T1DM receiving multiple subcutaneous injections of
insulin (MPII). Pregnant women with MPII in 100% cases of the presence of microalbuminuria and
proteinuria had premature delivery. Elevated levels of proinflammatory cytokines (IL-1β and
MCP-1) and TGF-β1 may possibly serve as a predictor of pre-term delivery in pregnant women
with diabetes type 1, starting with the early stages of pregnancy. The use of insulin by CSII in
pregnant women with T1DM reduces the percentage of pre-term deliveries, regardless of the
stage of diabetic nephropathy. It improves the condition of infants born at term in women with
T1DM using a therapy with insulin pumps compared to that with MPII such as less common
manifestation of diabetic fetopathy as macrosomia and hypoglycemia at birth, reducing the
need for resuscitation in newborns.
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